Growth hormone-mediated breakdown of body fat: insulin and leptin responses to GH are modulated by diet composition and caloric intake in old rats.
This work was performed to elucidate whether growth hormone (GH)-mediated loss of adipose tissue and responses in plasma insulin and leptin are modulated by diet composition. 12-month-old rats were first fed a high-fat (HF) diet or a low-fat (LF) diet for 14 weeks. After that, GH or saline was administered to rat groups that were maintained on either HF or LF diets or that were switched from the HF to the LF diet. All 6 groups had free access to food. One additional saline group was pair-fed with the GH group that was switched from the HF to the LF diet. The caloric consumption of this latter group was also translated to yet another GH group receiving restricted amounts of the HF diet. GH was given in a total dose of 4 mg/kg/d for three weeks. After sacrifice, blood was collected and tissues were excised. In groups injected with saline, the weight of excised adipose tissue was 60 +/- 4.7, 41 +/- 3.8 and 50 +/- 4.5 g in animals that continued with the HF diet, LF diet, or that were switched from HF to LF, respectively. Corresponding figures after GH treatment were significantly (p < 0.05) decreased to 38 +/- 2.7, 30 +/- 2.3, and 31 +/- 2.7 g, respectively. Pair-feeding had no effect, whereas only 26 +/- 3.0 g of adipose tissue was retrieved in rats fed restricted amounts of HF diet while receiving GH. In this group, plasma insulin and leptin were also significantly (p < 0.05) depressed compared with other GH groups, especially to the group fed the unrestricted HF diet (203 +/- 35 vs. 1345 +/- 160 pmol/l and 9.3 +/- 1.2 vs. 31 +/- 4.4 micro g/l). In conclusion, this study shows that GH mediates breakdown of adipose tissue under a variety of dietary conditions, and that induction of hyperinsulinemia can be prevented if GH treatment is combined with restricted feeding of a diet which is relatively low in carbohydrates and rich in fat. This will also promote a fall of plasma leptin.
Malmlöf
K
K
Department of Pharmacology 3, Pharmacology Research and Development, Novo Nordisk, Malov, Denmark. kmal@novonordisk.com
Johansen
T
T
D000273:Adipose Tissue / Q000187:drug effects* / Q000378:metabolism; D000367:Age Factors; D000824:Animal Nutritional Physiological Phenomena; D000818:Animals; D002849:Chromatography, Gas; D004041:Dietary Fats / Q000494:pharmacology; D002149:Energy Intake / Q000502:physiology*; D005260:Female; D013006:Growth Hormone / Q000378:metabolism / Q000494:pharmacology*; D007328:Insulin / Q000097:blood*; D020738:Leptin / Q000097:blood*; D051381:Rats; D017208:Rats, Wistar
D004041:Dietary Fats; D007328:Insulin; D020738:Leptin; D013006:Growth Hormone